About the Osteoarthritis Pain Drugs Market
Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement. It is also known as degenerative joint disease, hypertrophic arthritis, and degenerative arthritis, and is most commonly prevalent in older (above 60 years of age) and middle-aged people (between 40-59 years of age). The exact etiology of osteoarthritis is not well understood, but is believed to be an outcome of mechanical and molecular events in the affected joint. Increasing age, obesity, overuse of the joint, weak thigh muscles, and genetics are some of the common risk factors. Treatment is given depending upon the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise.
Technavio’s analysts forecast the global osteoarthritis pain drugs market to grow at a CAGR of 8.38% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global osteoarthritis pain drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat osteoarthritis pain. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Osteoarthritis Pain Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Abbott Laboratories
• Johnson & Johnson
• Novartis International
• Pfizer
Other prominent vendors
• AbbVie
• Abiogen Pharma
• Afferent Pharmaceuticals
• Astellas Pharma
• BioDelivery Sciences International
• Crystal Genomics
• Cytori Therapeutics
• Daiichi Sankyo
• Eli Lilly
• Endo Pharmaceuticals Holdings
• Horizon Pharma
• iCeutica
• Iroko Pharmaceuticals
• Merck
• Nuvo Research
• Regeneron Pharmaceuticals
• Sanofi
• SantoSolve
• Techfields Pharma
• Winston Pharmaceuticals
• Yooyoung Pharmaceutical
• Zynerba Pharmaceuticals
Market driver
• Significant unmet medical needs
• For a full, detailed list, view our report
Market challenge
• Preference for alternative therapies
• For a full, detailed list, view our report
Market trend
• Emergence of new treatments
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Key buying criteria
PART 05: Disease overview
• Understanding osteoarthritis
• Etiology and pathophysiology
• Risk factors
• Signs and symptoms
• Diagnosis
• Disease management
• Surgical treatment
• Epidemiology
• Economic burden of osteoarthritis
PART 06: Pipeline portfolio
• Information on pipeline candidates
• Ampion
• Tanezumab
• Zilretta (FX006)
• Fasinumab
• IP 880
• SoluMatrix Naproxen
• ABT-981
• AF-219
• ASP7962
PART 07: Osteoarthritis pain drugs: Clinical trials
PART 08: Opportunities for research in osteoarthritis
• Gaps between current research and possible research issues
• Challenges for vendors involved in osteoarthritis drug development
PART 09: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 10: Market segmentation by drug class
• NSAIDs
• Opioids
• Viscosupplements
• Corticosteroids
• Others
• Global NSAIDs market
• Global opioids market
• Global viscosupplements market
• Global corticosteroids market
PART 11: Market segmentation by ROA
• Oral
• Parenteral
• Topical
PART 12: Market segmentation by dosage form
• Solid
• Liquid
• Semi-solid
PART 13: Geographical segmentation
• Osteoarthritis pain drugs market in Americas
• Osteoarthritis pain drugs market in US
• Osteoarthritis pain drugs market in EMEA
• Osteoarthritis pain drugs market in APAC
PART 14: Market drivers
• Significant unmet medical needs
• Promising drug pipeline
• Increase in prevalence of osteoarthritis and obesity
PART 15: Impact of drivers
PART 16: Market challenges
• Preference for alternative therapies
• Loss of patent exclusivity of branded therapies
• Adverse effects of drugs
PART 17: Impact of drivers and challenges
PART 18: Market trends
• Emergence of new treatments
• Use of off-label drugs
• Strategic alliances
PART 19: Vendor landscape
• Competitive scenario
• Abbott Laboratories
• Johnson & Johnson
• Novartis
• Pfizer
• Other prominent vendors
PART 20: Upcoming vendors with novel approaches
• Ampio Pharmaceuticals
• Flexion Therapeutics
• Kitov Pharmaceuticals
PART 21: Appendix
• List of abbreviations
PART 22: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria
Exhibit 03: Types of osteoarthritis
Exhibit 04: Etiology and pathophysiology of osteoarthritis
Exhibit 05: Signs and symptoms of osteoarthritis
Exhibit 06: Diagnostic test for osteoarthritis
Exhibit 07: Treatment options for osteoarthritis
Exhibit 08: Non-pharmacological therapies used for osteoarthritis
Exhibit 09: Pharmacotherapy therapy for osteoarthritis
Exhibit 10: Surgical treatment
Exhibit 11: Economic burden of osteoarthritis
Exhibit 12: Distribution of direct costs of osteoarthritis
Exhibit 13: Cost analysis of treatment for individuals with osteoarthritis
Exhibit 14: Pipeline molecules for osteoarthritis pain
Exhibit 15: Osteoarthritis clinical trials by development phase
Exhibit 16: Share of Phase I, II, and III pipeline candidates in osteoarthritis pain drugs market
Exhibit 17: Osteoarthritis clinical trials by trial status
Exhibit 18: Highlights of osteoarthritis research opportunities:
Exhibit 19: Global osteoarthritis pain drugs market 2015-2020 ($ billions)
Exhibit 20: Current opportunities of osteoarthritis industry
Exhibit 21: Five forces analysis
Exhibit 22: Global osteoarthritis pain drugs market segmentation by drug class
Exhibit 23: Some NSAIDs used to treat osteoarthritis pain
Exhibit 24: Global osteoarthritis pain drugs market shares by drug class 2015
Exhibit 25: Global osteoarthritis pain drugs market segmentation by drug class 2015-2020 ($ billions)
Exhibit 26: Global osteoarthritis pain drugs market segmentation by drug class 2015-2020 percentage)
Exhibit 27: Global osteoarthritis pain drugs market 2015-2020
Exhibit 28: YoY growth rate of global osteoarthritis pain drugs market segments 2015-2020
Exhibit 29: Global NSAIDs market 2015-2020 ($ billions)
Exhibit 30: Global opioids market 2015-2020 ($ billions)
Exhibit 31: Global viscosupplements market 2015-2020 ($ billions)
Exhibit 32: Global corticosteroids market 2015-2020 ($ billions)
Exhibit 33: Global osteoarthritis pain drugs market segmentation by ROA
Exhibit 34: Global osteoarthritis pain drugs market segmentation by ROA 2015
Exhibit 35: Global osteoarthritis pain drugs market segmentation by dosage form
Exhibit 36: Global osteoarthritis pain drugs market segmentation by ROA 2015
Exhibit 37: Global osteoarthritis pain drugs market by geographical segmentation 2015
Exhibit 38: Global osteoarthritis pain drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 39: Global osteoarthritis pain drugs market revenue by geography 2015-2020
Exhibit 40: Global osteoarthritis pain drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 41: Osteoarthritis pain drugs market in Americas 2015-2020 ($ billions)
Exhibit 42: Osteoarthritis pain drugs market in Americas 2015
Exhibit 43: Osteoarthritis pain drugs market in US 2015-2020 ($ billions)
Exhibit 44: Osteoarthritis pain drugs market in EMEA 2015-2020 ($ billions)
Exhibit 45: Osteoarthritis pain drugs market in APAC 2015-2020 ($ billions)
Exhibit 46: Unmet medical needs with current osteoarthritis pain treatments
Exhibit 47: Prevalence of osteoarthritis in 2012 and 2022 (millions)
Exhibit 48: Average annual prevalence of osteoarthritis in US
Exhibit 49: Incidence of osteoarthritis in overweight and normal weight individuals 2013
Exhibit 50: Worldwide estimated osteoarthritis population growth 2010-2020
Exhibit 51: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 52: Expected growth of older population in US 2010-2050
Exhibit 53: Impact of drivers
Exhibit 54: Alternative therapies for osteoarthritis pain
Exhibit 55: Use of CAM therapies among individuals in US
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Future therapeutics in osteoarthritis pain treatment
Exhibit 58: Key takeaways
Exhibit 59: Key takeaways
Exhibit 60: Novartis: YoY revenue and growth rate of Voltaren 2013-2015 ($ millions)
Exhibit 61: Key takeaways
Exhibit 62: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ millions)
Exhibit 63: Pfizer: Geographical segmentation of Celebrex 2015
Exhibit 64: Key takeaways
Exhibit 65: Flexion Therapeutics: Pipeline products
Exhibit 66: Kitov Pharmaceuticals: Pipeline products
Exhibit 67: Osteoarthritis pain market size model
